Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes : Episode 6

Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1

January 20, 2025

By Javier Morales, MD, FACP, FACE
David Robertson, MD

Opinion

Video

Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.

EP: 1.Assessing the Burden of Type 1 Diabetes

EP: 2.Guidelines for Type 1 Diabetes Screening

EP: 3.Defining the Stages of Type 1 Diabetes

EP: 4.Impact of Delayed Intervention In Stage 2 Type 1 Diabetes

EP: 5.Screening for Autoantibodies in Type 1 Diabetes

Now Viewing

EP: 6.Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1

EP: 7.Clinical Trial Data for Teplizumab

EP: 8.Patient Selection for Teplizumab and Infusion Process

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!